Cash-Rich BioNTech Runs Seven Late-Stage Oncology Studies While Rewarding Shareholders

The Mainz-based biotech firm is balancing two bold moves in parallel: a $1 billion share buyback and a sweeping expansion of its late-stage oncology pipeline. While the stock has failed to rally on recent ASCO data, the underlying strategy is beginning to take shape. BioNTech’s shares closed at €78.80 on Monday, shedding 4.31% on the day and leaving the stock down 20.32% over the past twelve months. For a company sitting on €16.8 billion in cash and equivalents, the market’s skepticism stands in sharp contrast to its financial firepower.

Management has sanctioned a buyback program covering up to $1 billion—roughly 4.2% of outstanding shares—over twelve months. The move was reinforced by fresh institutional interest: Monaco Asset Management disclosed a $1.59 million stake. On the cost side, BioNTech is pressing ahead with a restructuring that could eliminate as many as 1,860 roles. Sites in Idar-Oberstein, Marburg, Singapore, as well as former CureVac facilities, will be vacated, generating annual savings of around €500 million by 2029. The freed capital is earmarked for oncology development.

The clinical engine is now running at full throttle. BioNTech confirmed in a June 1 SEC filing that it has seven global Phase 3 studies underway. Indications span non-small cell lung cancer (NSCLC), small cell lung cancer, breast cancer, colon cancer, and gastric cancer. At the center of this effort sits Pumitamig (BNT327), a bispecific PD-L1×VEGF-A antibody co-developed with Bristol Myers Squibb.

Data from the ROSETTA Lung-02 study, presented at ASCO in Chicago, underline Pumitamig’s potential. In the evaluable cohort of 40 patients (median follow-up 9.0 months), the combination with chemotherapy delivered a confirmed objective response rate of 57.1% in non-squamous NSCLC. In squamous disease, the figure jumped to 68.4%, with a disease control rate of 100%. Among patients with a PD-L1 tumor proportion score of 50% or higher, the confirmed response rate reached 100%, and lower dosing appeared to yield higher response rates. Safety was manageable: grade 3 or higher treatment-related adverse events occurred in 48.8% of patients, but only 23.3% were directly attributed to Pumitamig. The discontinuation rate stood at 9.3%. Truist Securities analysts viewed the data as competitive against rival therapies such as Ivonescimab from Summit and Akeso.

Should investors sell immediately? Or is it worth buying BioNTech?

Beyond ROSETTA Lung-02, BioNTech and Bristol Myers Squibb have launched two additional global Phase 3 trials. ROSETTA Lung-201 compares Pumitamig against Durvalumab after concurrent chemoradiation in unresectable Stage III NSCLC. ROSETTA Lung-202 pits Pumitamig against pembrolizumab in the first-line treatment of advanced, PD-L1-high NSCLC. The scope of the program is designed to position Pumitamig across multiple disease stages and patient subgroups.

The ASCO showcase extended beyond lung cancer. From the PRESERVE-004 Phase 2 study, Gotistobart plus pembrolizumab yielded durable antitumor activity in heavily pretreated, platinum-resistant ovarian cancer. Additional data covered antibody-drug conjugates targeting HER3, B7H3, and HER2, reflecting a pipeline that now encompasses more than 25 mid- to late-stage clinical trials, 13 of which are considered registration-enabling.

Analyst sentiment is cautiously constructive. UBS upgraded the stock from Neutral to Buy, lifting its price target to $135 from $117. Analyst David Dai called Pumitamig a credible candidate for a leading role in its drug class. UBS models €2.10 billion in revenue for BioNTech in 2026, rising to €4.44 billion by 2030, when it expects a net profit of €398 million. Jefferies maintains a Buy rating, and the consensus stands at Moderate Buy with an average target of $129.56. Berenberg and Canaccord Genuity have trimmed their targets to $140 and $158 respectively, but the overall tone remains bullish. The $1 billion buyback, alongside the €16.8 billion cash cushion, gives the company ample runway to fund the pipeline through these inflection points.

BioNTech at a turning point? This analysis reveals what investors need to know now.

The coming catalysts will be clinical, not financial. The ROSETTA Lung-02 expansion and the two companion Phase 3 studies must convert early signals into robust late-stage results. For a company transitioning from vaccine revenue to oncology, the next data readouts will determine whether the strategic overhaul is merely a compelling ASCO narrative—or the foundation of a new commercial reality.

Ad

BioNTech Stock: New Analysis - 2 June

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | CASH-RICH | boerse | 69467995 |